Iterative Scopes appoints new CTO  

Precision medicine technologies company Iterative Scopes has appointed a new Chief Technology Officer (CTO) to help lead the business’ machine learning offerings.  

Dr Aditya Khosla has joined the team as CTO and as a member of Iterative Scopes’ board of directors. In his role as CTO, Dr Khosla will lead Iterative Scopes’ machine learning, product management, and software engineering teams. 

Before joining Iterative Scopes, Dr Khosla was the co-founder and CTO of PathAI, where he led the engineering and IT, machine learning, product, and recruiting teams. The company has grown to become the leading provider of AI-powered research tools and services for pathology. During his tenure as CTO and co-founder, PathAI raised over $250M from leading investors, and now employs over 700 people. 

Official comments  

“We are thrilled to welcome Dr Khosla to the Iterative Scopes team,” says Jonathan Ng, MBBS, founder and CEO of Iterative Scopes. “Aditya brings a dedicated expertise in machine learning and improving patient outcomes with AI-powered healthcare technologies.” 

“I’ve gotten to know Aditya over the past four years at MIT where I had the privilege of attending his lectures, as an advisor to the company and mentor to myself, and now coming full circle as a teammate at Iterative Scopes,” added Dr Ng. “I am incredibly excited for Aditya to bring his scientific leadership and operational expertise to Iterative Scopes to unlock a new generation of AI tools in gastroenterology.” 

“I’m excited to join Iterative Scopes as it makes significant inroads toward eliminating the disparities in care for the treatment of GI diseases,” says Dr Khosla. “Its application of real-time, computer-vision-based technologies for precision medicine has the potential to benefit millions of patients at their point of care. I’m looking forward to applying my background and skills to drive discovery and predictive diagnostics that support the Iterative Scopes mission.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free